QQQ   267.51 (+0.24%)
AAPL   110.08 (+3.03%)
MSFT   202.54 (+1.07%)
FB   248.15 (-1.73%)
GOOGL   1,430.14 (-1.44%)
AMZN   2,960.47 (+0.19%)
NVDA   500.69 (+2.69%)
TSLA   449.39 (+1.64%)
BABA   273.82 (+0.52%)
CGC   15.74 (-3.79%)
GE   6.35 (-7.70%)
MU   49.15 (-3.13%)
AMD   77.94 (+4.02%)
T   28.63 (-1.04%)
F   6.87 (-4.98%)
ACB   6.32 (-3.22%)
GILD   64.21 (-1.29%)
NFLX   487.35 (+3.70%)
DIS   125.41 (-2.50%)
BAC   24.47 (-2.94%)
BA   156.35 (-2.97%)
QQQ   267.51 (+0.24%)
AAPL   110.08 (+3.03%)
MSFT   202.54 (+1.07%)
FB   248.15 (-1.73%)
GOOGL   1,430.14 (-1.44%)
AMZN   2,960.47 (+0.19%)
NVDA   500.69 (+2.69%)
TSLA   449.39 (+1.64%)
BABA   273.82 (+0.52%)
CGC   15.74 (-3.79%)
GE   6.35 (-7.70%)
MU   49.15 (-3.13%)
AMD   77.94 (+4.02%)
T   28.63 (-1.04%)
F   6.87 (-4.98%)
ACB   6.32 (-3.22%)
GILD   64.21 (-1.29%)
NFLX   487.35 (+3.70%)
DIS   125.41 (-2.50%)
BAC   24.47 (-2.94%)
BA   156.35 (-2.97%)
QQQ   267.51 (+0.24%)
AAPL   110.08 (+3.03%)
MSFT   202.54 (+1.07%)
FB   248.15 (-1.73%)
GOOGL   1,430.14 (-1.44%)
AMZN   2,960.47 (+0.19%)
NVDA   500.69 (+2.69%)
TSLA   449.39 (+1.64%)
BABA   273.82 (+0.52%)
CGC   15.74 (-3.79%)
GE   6.35 (-7.70%)
MU   49.15 (-3.13%)
AMD   77.94 (+4.02%)
T   28.63 (-1.04%)
F   6.87 (-4.98%)
ACB   6.32 (-3.22%)
GILD   64.21 (-1.29%)
NFLX   487.35 (+3.70%)
DIS   125.41 (-2.50%)
BAC   24.47 (-2.94%)
BA   156.35 (-2.97%)
QQQ   267.51 (+0.24%)
AAPL   110.08 (+3.03%)
MSFT   202.54 (+1.07%)
FB   248.15 (-1.73%)
GOOGL   1,430.14 (-1.44%)
AMZN   2,960.47 (+0.19%)
NVDA   500.69 (+2.69%)
TSLA   449.39 (+1.64%)
BABA   273.82 (+0.52%)
CGC   15.74 (-3.79%)
GE   6.35 (-7.70%)
MU   49.15 (-3.13%)
AMD   77.94 (+4.02%)
T   28.63 (-1.04%)
F   6.87 (-4.98%)
ACB   6.32 (-3.22%)
GILD   64.21 (-1.29%)
NFLX   487.35 (+3.70%)
DIS   125.41 (-2.50%)
BAC   24.47 (-2.94%)
BA   156.35 (-2.97%)
Log in
NASDAQ:SCYX

SCYNEXIS Stock Forecast, Price & News

$5.00
-0.34 (-6.37 %)
(As of 09/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.95
Now: $5.00
$5.25
50-Day Range
$4.86
MA: $5.93
$7.27
52-Week Range
$4.54
Now: $5.00
$14.40
Volume50,579 shs
Average Volume96,265 shs
Market Capitalization$53.01 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase 2 clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Read More
SCYNEXIS logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SCYX
CUSIPN/A
Phone201-884-5485

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$120,000.00
Book Value$1.32 per share

Profitability

Net Income$-53,710,000.00

Miscellaneous

Employees27
Market Cap$53.01 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$5.00
-0.34 (-6.37 %)
(As of 09/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions

How has SCYNEXIS's stock been impacted by Coronavirus?

SCYNEXIS's stock was trading at $7.8020 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SCYX shares have decreased by 35.9% and is now trading at $5.00.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of SCYNEXIS?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for SCYNEXIS
.

When is SCYNEXIS's next earnings date?

SCYNEXIS is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for SCYNEXIS
.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS Inc (NASDAQ:SCYX) released its earnings results on Monday, August, 10th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.88) by $0.24.
View SCYNEXIS's earnings history
.

When did SCYNEXIS's stock split? How did SCYNEXIS's stock split work?

Shares of SCYNEXIS reverse split before market open on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of SCYNEXIS stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for SCYX?

5 brokerages have issued 1-year price targets for SCYNEXIS's shares. Their forecasts range from $25.00 to $50.00. On average, they anticipate SCYNEXIS's stock price to reach $39.00 in the next year. This suggests a possible upside of 680.0% from the stock's current price.
View analysts' price targets for SCYNEXIS
.

Are investors shorting SCYNEXIS?

SCYNEXIS saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 139,300 shares, a decline of 25.1% from the August 15th total of 186,000 shares. Based on an average daily volume of 77,400 shares, the short-interest ratio is presently 1.8 days. Currently, 1.4% of the company's stock are sold short.
View SCYNEXIS's Short Interest
.

Who are some of SCYNEXIS's key competitors?

What other stocks do shareholders of SCYNEXIS own?

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the following people:
  • Dr. Marco Taglietti, CEO, Pres & Director (Age 60, Pay $937.35k)
  • Mr. Eric Francois, Chief Financial Officer (Age 45, Pay $604.91k)
  • Mr. David Gonzalez Angulo, Chief Medical Officer (Age 55, Pay $676.13k)
  • Mr. Scott Sukenick J.D., Gen. Counsel & Corp. Sec. (Age 42)

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

Who are SCYNEXIS's major shareholders?

SCYNEXIS's stock is owned by many different institutional and retail investors. Top institutional shareholders include Bridgeway Capital Management Inc. (5.14%), Creative Planning (2.10%), Charles Schwab Investment Management Inc. (1.04%), D.A. Davidson & CO. (0.89%) and Advisor Group Holdings Inc. (0.32%). Company insiders that own SCYNEXIS stock include Gonzalez David Angulo and Marco Taglietti.
View institutional ownership trends for SCYNEXIS
.

Which institutional investors are buying SCYNEXIS stock?

SCYX stock was bought by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Charles Schwab Investment Management Inc., D.A. Davidson & CO., Advisor Group Holdings Inc., and Creative Planning. Company insiders that have bought SCYNEXIS stock in the last two years include Gonzalez David Angulo, and Marco Taglietti.
View insider buying and selling activity for SCYNEXIS
.

How do I buy shares of SCYNEXIS?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $5.00.

How big of a company is SCYNEXIS?

SCYNEXIS has a market capitalization of $53.01 million and generates $120,000.00 in revenue each year. The company earns $-53,710,000.00 in net income (profit) each year or ($8.10) on an earnings per share basis. SCYNEXIS employs 27 workers across the globe.

What is SCYNEXIS's official website?

The official website for SCYNEXIS is www.scynexis.com.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.